5% Imiquimod cream for external anogenital warts in HIV-infected patients under HAART therapy.
The efficacy of imiquimod in the treatment of external genital warts in HIV positive subjects was compared to a group of patients with normal immune function. Imiquimod 5% cream was applied by patients three times a week until resolution for a maximum of 16 weeks. Assessment for response and the occurrence of side effects was performed every four weeks. Thirty-one per cent of 75 HIV positive patients achieved a complete clearance, a partial response was obtained in 24% of subjects while in 45% we observed no clinical response. In the control group a total clearance was obtained in 62% of subjects, a partial response in 24% and no response in 14%. Recurrences occurred in 4/23 HIV patients and 2/31 immunocompetent patients within three months of follow-up. Side effects were minor to moderate. We conclude that imiquimod 5% cream has an acceptable efficacy and safety on HIV patients.
Cusini
M
M
Centro Malattie a Trasmissione Sessuale, Istituto di Scienze Dermatologiche, IRCCS Ospedale Maggiore Milano, Via Pace 9, 20122 Milan, Italy. centromts@policlinico.mi.it
Salmaso
F
F
Zerboni
R
R
Carminati
G
G
Vernaci
C
C
Franchi
C
C
Locatelli
A
A
Alessi
E
E
D000279:Administration, Cutaneous; D000328:Adult; D000634:Aminoquinolines / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D023241:Antiretroviral Therapy, Highly Active; D001004:Anus Diseases / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D016022:Case-Control Studies; D003218:Condylomata Acuminata / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D004334:Drug Administration Schedule; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D000077271:Imiquimod; D008297:Male; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000634:Aminoquinolines; D000970:Antineoplastic Agents; D000077271:Imiquimod